Springworks Therapeutics, Inc., A Healthcare Company Of Merck Kgaa, Darmstadt, Germany
Clinical trials sponsored by Springworks Therapeutics, Inc., A Healthcare Company Of Merck Kgaa, Darmstadt, Germany, explained in plain language.
-
New drug tested for rare tumors in young women
Disease control Recruiting nowThis study tests the drug nirogacestat in 50 premenopausal women (ages 18-40) with desmoid tumors, a rare type of non-cancerous growth. The main goal is to see how the drug affects ovarian function and to monitor any side effects. Participants will take the drug and be followed f…
Phase: PHASE4 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 17, 2026 09:38 UTC
-
Last-Resort drug access for rare tumor patients
Disease control AVAILABLEThis program provides nirogacestat to individual patients with serious desmoid tumors or NOTCH gene mutation positive tumors who have no other treatment options and cannot join a clinical trial. The goal is to control the disease when standard therapies have failed. Approval is n…
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 17, 2026 09:37 UTC